Info

Tibotec, a division of Janssen-Cilag is commercializing PREZISTA in Europe. TMC120, Tibotec's first NNRTI in clinical development, was licensed to the International Partnership for Microbicides for its development as a vaginal microbicide in March 2004. TMC207, a novel anti-TB compound was transferred from Johnson & Johnson PRD to Tibotec for clinical development and is currently in Phase II testing. In the field of Hepatitis C virus, Tibotec obtained certain ex-US rights to VX-950, an investigational oral inhibitor of hepatitis C virus protease in Phase II development from Vertex. In addition, Tibotec has internal preclinical HCV drug discovery programs, and has also licensed candidate HCV protease inhibitors from Medivir in a collaboration from which a designated candidate drug, TMC435350, has entered phase Ib.